- Sixth Wave Innovations Inc.’s (SIXW) patent-pending AMIPs™ technology successfully detects the SARS-CoV-2 virus
- Sixth Wave has successfully completed initial testing of Integration of the first microarray architecture into an AMIPs™ prototype
- Initial viral selectivity screening experiments have validated AMIPs™ ability to screen between COVID-19 and other non-enveloped viruses
- The AMIPs™ technology provides an opportunity for less invasive and less expensive testing
- Sixth Wave Innovations Inc.’s (SIXW) is unchanged trading at $0.18 per share as of 12:58 p.m. EST
Sixth Wave Innovations Inc.’s (SIXW) patent-pending AMIPs™ technology successfully detects the SARS-CoV-2 virus.
It tests in saliva samples at sensitivity levels comparable to commercially available antigen tests.
The AMIPsTM testing is low-cost, highly accurate, and simple to use.
Sixth Wave has successfully completed initial testing of the integration of the first microarray architecture into an AMIPs™ prototype.
This advancement achieves another company goal toward increased sensitivity and selectivity against other respiratory pathogens.
Testing and optimization for production are ongoing.
Initial viral selectivity screening experiments have validated AMIPs’ ability to screen between COVID-19 and other non-enveloped viruses.
Working with researchers at the Li Ka Shing Institute of Virology at the University of Alberta, clinical tests were performed using saliva samples spiked with live SARS-CoV-2 virus.
The battery of tests produced results down to published detection levels for antigen tests.
The ability to detect the virus in saliva samples is considered a critical diagnostic tool in working against the pandemic.
The AMIPs™ technology provides an opportunity for less invasive, less expensive testing, without the limiting storage and handling requirements of an antigen test.
The COVID-19 diagnostic market is expected to grow from $84.4 billion in 2021 to $195.1 billion by 2027, at a compound annual growth rate of 15 per cent.
Sixth Wave is not making any claims that its current AMIPs™ product can eliminate, cure, contain, at a commercial level, COVID-19, or SARS-2 coronavirus, as of now.
Sixth Wave Innovations Inc.’s (SIXW) is unchanged trading at $0.18 per share as of 12:58 p.m. EST.
